New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Findsnews2022-03-30T22:45:15+00:00March 30th, 2022|The New York Times|
Pfizer Recalls Some Blood Pressure Drugs, Citing Cancer Risknews2022-03-23T20:29:21+00:00March 23rd, 2022|The New York Times|
Senate Confirms Califf as F.D.A. Chief in Tight Votenews2022-02-15T18:47:59+00:00February 15th, 2022|The New York Times|
FDA Panel Rejects Lilly’s Cancer Drug Tested Only in Chinanews2022-02-10T22:41:51+00:00February 10th, 2022|The New York Times|
C.D.C. Proposes New Guidelines for Treating Pain, Including Opioid Usenews2022-02-10T13:55:27+00:00February 10th, 2022|The New York Times|
Senate Panel OKs Califf Nomination for F.D.A. Chiefnews2022-01-14T04:32:55+00:00January 14th, 2022|The New York Times|
Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelmnews2022-01-12T01:22:10+00:00January 12th, 2022|The New York Times|
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decisionnews2021-12-31T21:39:22+00:00December 31st, 2021|The New York Times|
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstaclesnews2021-12-21T02:08:14+00:00December 21st, 2021|The New York Times|
F.D.A. Will Permanently Allow Abortion Pills by Mailnews2021-12-17T00:37:15+00:00December 17th, 2021|The New York Times|
